International Journal of Research in Medical Sciences
Mannava AS et al. Int J Res Med Sci. 2023 Sep;11(9):3589-3590
www.msjonline.org
pISSN 2320-6071 | eISSN 2320-6012
DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20232823

Letter to the Editor

The eyes don't see what the mind doesn't know: discovering monoclonal gammopathy of thrombotic or thrombocytopenic significance

Sir,

A new scientific advancement in the field of medicine has been made thanks to the collaboration between the university of Michigan health and mayo clinic. A previously undiscovered illness has been named Monoclonal Gammopathy of Thrombotic/Thrombocytopenic Significance (MGTS) as a result of thorough investigation and the convergence of facts.[1] The ramifications of this discovery for medical professionals are considerable, and they may lead to a radical change in how we approach patient care, diagnosis, and treatment.

A pivotal event in medical history has been marked by the discovery of MGTS as a novel disease. It makes us pause and consider how quickly medical knowledge can change. The possibility that this disease went undiagnosed for a long time highlights the complexity and subtleties that can elude even the most accomplished medical brains. This finding demonstrates the value of ongoing investigation and cooperation in locating mysterious medical phenomena.

Even though MGTS is uncommon, it offers a complex problem that necessitates in-depth comprehension and all-encompassing management. As a result of immune system disruption brought on by MGTS, malignant plasma cells in affected individuals create monoclonal immunoglobulins that selectively target platelet factor 4 (PF4). These antibodies produce Antigen-antibody complexes, which start off a series of events that lead to the creation of recurring thrombi in various parts of the body. As a result, patients may experience a variety of symptoms, from thrombotic presentations like deep vein thrombosis, pulmonary embolism, or stroke to thrombocytopenia-related symptoms like easy bleeding and bruising.

This recently discovered condition has a relationship to the more general class of monoclonal gammopathy, which is represented by monoclonal gammopathy of undetermined significance (MGUS). The identification of MGTS highlights the possibility that subgroups within this category could have a significant therapeutic impact, even though MGUS frequently remains asymptomatic and is incidentally detected. Monoclonal immunoglobulins, often known as M proteins, are produced in MGUS and its counterparts such as multiple myeloma (MM). These proteins don't normally have the same ability to attach to the same antigens as their regular antibody counterparts. When M proteins build up in the enlarged lamellae of myelin fibres, they cause demyelination, which is a similar, phenomena seen in other monoclonal gammopathies like Waldenstrom macroglobulinemia and MM.[2,3] This results in blood thickening and, in some circumstances, peripheral neuropathy in MGUS patients.[2]

Given the distinct mechanism behind thrombosis in this setting, it is crucial to distinguish MGTS from traditional monoclonal gammopathies. In contrast to those linked to MGUS and MM, the risk factors and triggers that contribute to arterial and venous thrombosis in MGTS are unique. In MM, treatment with thalidomide or lenalidomide concomitantly with anthracyclines or dexamethasone further increases the risk for arterial and venous thrombosis.[4] This discrepancy calls for specialised consideration from medical specialists in order to develop precise diagnosis methods and individualised treatment plans.

Beyond thrombotic events and symptoms connected to thrombocytopenia, MGTS has additional clinical manifestations. The abnormal M proteins produced by malignant plasma cells can lead to a variety of difficulties for patients with MGTS. These proteins can have systemic effects that affect different organ systems and result in a wide range of symptoms. To fully appreciate the wide-ranging ramifications of MGTS, a thorough investigation of the complex web of connections between M proteins, immunological responses, and the vascular system is necessary.

The door to ground-breaking therapeutic options swings open as the medical community stands on the verge of this revolutionary discovery. The unique immunological foundations of MGTS offer a special canvas on which cutting-edge therapeutic approaches can be painted. The potential for changing the course of the disease, reducing the risk of thrombosis, and treating associated symptoms exists with targeted medicines that try to sabotage the antibody-antigen interactions unique to MGTS. In light of complicated and once cryptic illnesses, the therapeutic landscape for MGTS is changing, which is a monument to the transformational power of medical science. It also highlights the potential for better patient outcomes.

The joint efforts of the university of Michigan health and mayo clinic have not only discovered a novel medical entity but have also sparked widespread interest among medical professionals. This finding should serve as a wake-up call for medical practitioners to embrace the spirit of innovation and research, push the limits of what is currently known about medicine, and approach every patient interaction with an open mind.

MGTS stands for a thread of discovery that connects the threads of technology development and human brilliance in the magnificent tapestry of medical progress. It reflects the spirit of medical curiosity and serves as a reminder that there are still areas of the human body that need to be investigated. As they set out on a quest to understand the intricacies of MGTS, researchers and practitioners stand poised to have a profound effect on the lives of those affected by this disorder and to influence the future of medical practice.

CONCLUSION

In conclusion, the finding of MGTS is a sobering reminder of the vast untapped potential for medical science research. This newly discovered information symbolises a paradigm change, a test of traditional wisdom, and an invitation to look behind the surface of medical issues. It goes beyond simple clinical observation. As MGTS assumes its position on the stage of medical comprehension, it sets off on a journey of research and inquiry, shedding light on the complex web of human health and providing promise for improved patient care, enhanced diagnostics, and cutting-edge treatment modalities.

Anjali Srikanth Mannava*,
Raja Narendra Divakar Addanki

Department of Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

***Correspondence to,**
Dr. Anjali Srikanth Mannava,
anjalisrikanth9@gmail.com

REFERENCES

1. Kanack AJ, Schaefer JK, Sridharan M, Splinter NP, Kohlhagen MC, Singh B et al. Monoclonal gammopathy of thrombotic/thrombocytopenic significance. Blood. 2023;141(14):1772-6.
2. Lach B, Rippstein P, Atack D, Afar DE, Gregor A. Immunoelectron microscopic localization of monoclonal IgM antibodies in gammopathy associated with peripheral demyelinative neuropathy. Acta neuropathologica. 1993;85(3):298-307.
3. Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clinic Proceedings. 2017;92(5):838-50.
4. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology (Amsterdam, Netherlands). 2012;17(1):S177-80.

Cite this article as: Mannava AS, Addanki RND. The eyes don't see what the mind doesn't know: discovering monoclonal gammopathy of thrombotic or thrombocytopenic significance. Int J Res Med Sci 2023:11:3589-90.